Development

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Articles

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

Can Vaccine Development Be Safely Accelerated?

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Considering the potential interaction of a drug with the delivery device early on in in development is integral to achieving the best combination.

Avoiding Negative Drug–Device Interactions

The new molecules entering the development pipeline are bringing forth exciting challenges in drug delivery.

Delivering the Goods

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

The need for manufacturing speed inspires contract manufacturers to explore advanced processing technologies.

More Capacity and Technology Translate to More Options

A new sucrose product from MilliporeSigma has reduced nanoparticle impurities.

Low-Impurity Sucrose Lowers Risk of Protein Instability in Biopharmaceutical Formulation

A complete understanding of primary packaging physicochemical properties is necessary in the formulation and development of biologics.

Formulation and Development Considerations for Biologics

On Tuesday, Nov. 5, 2019, Karima Yadi from Becton Dickinson & Co. will present the challenges of using, and necessity for, shorter needles and integrated systems with high viscosity drugs, such as biologics, to improve the patient experience at CPhI Worldwide.

Improving the Patient Experience with High Viscosity/High Volume Drugs

Lipid-based formulations provide a versatile solution to bioavailability issues, but a multi-disciplinary approach is needed to overcome limitations with poorly soluble compounds.


Overcoming Bioavailability ‘Roadblocks’ with LBDDS

john Hammond is Technical & Marketing Manager with Starna Scientific Limited, 52-54 Fowler Road, Hainault Business Park, Hainault, Essex, IG6 3UT, UK

Nancy Lewen is research fellow, CSD Analytical chemistry, Bristol-Myers Squibb.

Emmanuel Akala is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Anthony Hickey is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients.

Jolyon Mitchell is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

June Liang is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Timothy Shelbourn is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Katherine Tyner is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Eloise Welfare is a members of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Norbert Maurer is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Munir Hussain is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Lawrence Block is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Myke Scoggins is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

Thomas Tice is a member of the Joint Subcommittee of the United States Pharmacopeia Expert Committees on Dosage Forms, Chemical Analysis, Physical Analysis, and Excipients

In this article, the contents of a stimulus article produced by the joint subcommittee of the USP Expert Committees on Dosage Forms, Physical Analysis, and Excipients and relevant comments from a workshop session are summarized.


Perspectives on Quality Attributes of Drug Products Containing Nanomaterials

Innovation in manufacturing technologies must occur to ensure the availability of gene therapies and cell therapies.

Formulation and Drug Delivery, Biologic Drugs